Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stoke Therapeutics Inc.

www.stoketherapeutics.com

Latest From Stoke Therapeutics Inc.

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.

Financing Business Strategies

Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue

Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.

Financing Business Strategies

Venture Funding Deals: Gotham Raises $54m To Advance Epitranscriptomics

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced September and October 2018.
Deals Financing

Finance Watch: Investors Can't Get Enough Of NASH, Including Start-Ups With Novel Drugs

Terns raised an $80m Series B round for NASH and cancer programs, while 89Bio launched with a $60m Series A to fund drugs for NASH and other liver and metabolic diseases. Also, Stoke leads recent VC deals with $90m Series B.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Stoke Therapeutics Inc.
  • Senior Management
  • Edward M Kaye, MD, CEO
    Stephen J Tulipano, CFO
    Huw M Nash, PhD, COO & CBO
    Barry S Ticho, MD, PhD, CMO
    Gene Liau, PhD, EVP, Head, Research & Preclinical Dev.
    Shamim Ruff, SVP, Reg. Affairs & Quality
    Nancy M Wyant, VP, Head Clinical Operations
  • Contact Info
  • Stoke Therapeutics Inc.
    Phone: (781) 430-8200
    45 Wiggins Ave.
    Bedford, MA 01730
    USA
UsernamePublicRestriction

Register